{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T14:17:47Z","timestamp":1781014667835,"version":"3.54.1"},"reference-count":29,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2008,8,13]],"date-time":"2008-08-13T00:00:00Z","timestamp":1218585600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Transplantation"],"published-print":{"date-parts":[[2008,11]]},"abstract":"<jats:p><jats:bold>Abstract:\u2002<\/jats:bold> Varicella\u2010Zoster virus infection (VZV) has a high incidence post\u2010allogeneic peripheral blood stem cell transplant (PBSCT). However, data regarding long\u2010term acyclovir prophylaxis for VZV prevention are limited. We evaluated the clinical efficacy of long\u2010term low\u2010dose acyclovir prophylaxis for VZV infection after allogeneic PBSCT at the Princess Margaret Hospital (PMH), Canada and the Kyungpook National University Hospital (KNUH), Korea. The acyclovir prophylaxis regimen at PMH was acyclovir 400\u2003mg\/d orally until engraftment, and at KNUH was acyclovir 800\u2003mg\/d orally until immunosuppression discontinuation. Long\u2010term acyclovir prophylaxis was given to 26\/193 (14%) patients in the PMH group and 73\/79 (92%) patients in the KNUH group. In the PMH group, 42 cases (22%) developed VZV infection, while six cases (8%) had VZV infection in the KNUH group (p\u2003=\u20030.005). With a median of 26.5\u2003months of follow\u2010up, the incidences of VZV infection at one and two yr were 15.8% and 20.7% in the PMH group, and 2.5% and 5.8% in the KNUH group, respectively (p\u2003=\u20030.001). By controlling the other potential risk factors for VZV infection in multivariate analysis, the use of long\u2010term acyclovir was the only protective factor for VZV infection after allogeneic PBSCT (p\u2003=\u20030.04, hazard ratio\u2003=\u20030.296). Long\u2010term use of acyclovir appears to be protective for VZV infection after allogeneic PBSCT, especially during the period of immunosuppressive therapy.<\/jats:p>","DOI":"10.1111\/j.1399-0012.2008.00877.x","type":"journal-article","created":{"date-parts":[[2010,8,19]],"date-time":"2010-08-19T11:56:12Z","timestamp":1282218972000},"page":"770-779","source":"Crossref","is-referenced-by-count":28,"title":["Clinical efficacy of prophylactic strategy of long\u2010term low\u2010dose acyclovir for Varicella\u2010Zoster virus infection after allogeneic peripheral blood stem cell transplantation*"],"prefix":"10.1111","volume":"22","author":[{"given":"Dong Hwan","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepali","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans A.","family":"Messner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Minden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikas","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Kuruvilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yee Soo","family":"Chae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Kyun","family":"Sohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey H.","family":"Lipton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2008,11,11]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1083-8791(00)70051-6"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-3062.2007.00247.x"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1702119"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/152.6.1172"},{"key":"e_1_2_5_6_2","first-page":"659","article-title":"Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients","volume":"6","year":"2000","journal-title":"Biol Blood Marrow Transplant"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2001.1.392"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1701796"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.1998.230_a.x"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2257.2001.00397.x"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1702599"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705727"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705130"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1703790"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-01-0048"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2004.00249.x"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2004.04891.x"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1086\/342965"},{"key":"e_1_2_5_19_2","first-page":"185","article-title":"Long\u2010term acyclovir prophylaxis in bone marrow transplant recipients and lymphocyte proliferation responses to herpes virus antigens in vitro","volume":"1","author":"Ljungman P","year":"1986","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1989.88"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1703214"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1704959"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-03-077644"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.18.3.443"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.74.12.5716"},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(18)83248-3"},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(88)70029-8"},{"key":"e_1_2_5_28_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.31.8.1238"},{"key":"e_1_2_5_29_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1704636"},{"key":"e_1_2_5_30_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-144-6-200603210-00007"}],"container-title":["Clinical Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1399-0012.2008.00877.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1399-0012.2008.00877.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T20:47:07Z","timestamp":1696884427000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1399-0012.2008.00877.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,11]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2008,11]]}},"alternative-id":["10.1111\/j.1399-0012.2008.00877.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1399-0012.2008.00877.x","archive":["Portico"],"relation":{},"ISSN":["0902-0063","1399-0012"],"issn-type":[{"value":"0902-0063","type":"print"},{"value":"1399-0012","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,11]]}}}